Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;87(3):1589-1590.
doi: 10.1111/bcp.14476. Epub 2020 Jul 17.

Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19

Ricardo Peña-Silva  1   2 , Stephen B Duffull  3 , Andrew C Steer  4   5   6 , Sandra X Jaramillo-Rincon  1   7 , Amanda Gwee  4   5   6 , Xiao Zhu  3
Affiliations

Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19

Ricardo Peña-Silva et al. Br J Clin Pharmacol. 2021 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

There are no competing interests to declare.

Figures

FIGURE 1
FIGURE 1
Expected free plasma concentrations of ivermectin based on 93% binding to plasma proteins and previously published total plasma concentrations., , When necessary, an estimated body weight of 70 kg was used for calculations. Note that none of the doses reached the 5μM concentration required for the antiviral effect of ivermectin (dotted line)
See this image and copyright information in PMC

References

    1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA‐approved drug ivermectin inhibits the replication of SARS‐CoV‐2 in vitro. Antiviral Res. 2020;178:104787. - PMC - PubMed
    1. Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen(R)‐based assay for high‐throughput screening for specific inhibitors of nuclear import. J Biomol Screen. 2011;16(2):192‐200. - PubMed
    1. Smit MR, Ochomo EO, Waterhouse D, et al. Pharmacokinetics‐pharmacodynamics of high‐dose Ivermectin with dihydroartemisinin‐piperaquine on mosquitocidal activity and QT‐prolongation (IVERMAL). Clin Pharmacol Ther. 2019;105(2):388‐401. - PMC - PubMed
    1. Duthaler U, Suenderhauf C, Karlsson MO, et al. Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. Br J Clin Pharmacol. 2019;85(3):626‐633. - PMC - PubMed
    1. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122‐1133. - PubMed

Publication types

MeSH terms

Grants and funding